ASCO 2025: PRESERVE-006: Phase 1 Study of Gotistobart (BNT316/ONC-392) in Combination with Lutetium Lu 177 Vipivotide Tetraxetan in Patients with mCRPC

Full report from UroToday: https://www.urotoday.com/conference-highlights/asco-2025/asco-2025-prostate-cancer/160813-asco-2025-preserve-006-phase-1-study-of-gotistobart-bnt316-onc-392-in-combination-with-lutetium-lu-177-vipivotide-tetraxetan-in-patients-with-mcrpc.html

The release as fetched from its publisher. oncoc4.com ↗